Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing
Abstract The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of un...
Gespeichert in:
| Veröffentlicht in: | Breast (Edinburgh) 2012-12, Vol.21 (6), p.724-729 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 729 |
|---|---|
| container_issue | 6 |
| container_start_page | 724 |
| container_title | Breast (Edinburgh) |
| container_volume | 21 |
| creator | Pathmanathan, Nirmala Provan, Pamela J Mahajan, Hema Hall, Geoffrey Byth, Karen Bilous, A. Michael Balleine, Rosemary L |
| description | Abstract The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of universal testing. In 2003/4, 43.3% of breast cancers were tested for HER2 with 16% of tested cases HER2+. In 2008/9, 98.4% of cases were tested with 14.7% HER2+. In 2008/9, HER2+ status was associated with younger age, higher grade, increased tumour size, lymph node involvement, negative oestrogen and/or progesterone receptor status. HER2+ cases diagnosed in 2003/4 were not significantly different in respect of these features. The rate of HER2+ breast cancer amongst screen detected cases in 2008/9 was 8.3%. The phenotype of HER2+ breast cancer was stable following the introduction of universal testing. The overall rate of HER2+ breast cancer was influenced by screen detection. |
| doi_str_mv | 10.1016/j.breast.2012.09.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1178671941</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0960977612001877</els_id><sourcerecordid>1178671941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-6a6d5687e4932e0b4cd599179a0c8169e25ed79d8229f93f7a4d1d8364b4318e3</originalsourceid><addsrcrecordid>eNqFkU2PFCEURYnROO3oPzCmlm6qfEA1FBsT0xkdk0lM_FgTGl710FZDC9SY-fdS1ujCjSs299wbziPkJYWOAhVvjt0-ocmlY0BZB6oDoI_Ihm45azkM8JhsQAlolZTigjzL-QgAiovhKblgHJRiIDfktLs1ydiCyefibW7i2FxffWbtOWZf_B0260pjTbCYGufNIcSMrhnjNMWfPhyacouNDyVFN9viY1g65lDZlM30u60pWNvD4Tl5Mpop44uH95J8e3_1dXfd3nz68HH37qa1vRKlFUa4rRgk9oozhH1v3VYpKpUBO1ChkG3RSeUGxtSo-ChN76gbuOj3PacD8kvyeu09p_hjrtv65LPFaTIB45w1pXIQkqqe1mi_Rm2KOScc9Tn5k0n3moJeROujXhXoRbQGpavoir16WJj3J3R_oT9ma-DtGsD6zzuPSWfrsTp0PqEt2kX_v4V_C-zkg7dm-o73mI9xTqE61FTnyugvy7GXW1NW6UFK_gsHZKYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1178671941</pqid></control><display><type>article</type><title>Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Pathmanathan, Nirmala ; Provan, Pamela J ; Mahajan, Hema ; Hall, Geoffrey ; Byth, Karen ; Bilous, A. Michael ; Balleine, Rosemary L</creator><creatorcontrib>Pathmanathan, Nirmala ; Provan, Pamela J ; Mahajan, Hema ; Hall, Geoffrey ; Byth, Karen ; Bilous, A. Michael ; Balleine, Rosemary L</creatorcontrib><description>Abstract The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of universal testing. In 2003/4, 43.3% of breast cancers were tested for HER2 with 16% of tested cases HER2+. In 2008/9, 98.4% of cases were tested with 14.7% HER2+. In 2008/9, HER2+ status was associated with younger age, higher grade, increased tumour size, lymph node involvement, negative oestrogen and/or progesterone receptor status. HER2+ cases diagnosed in 2003/4 were not significantly different in respect of these features. The rate of HER2+ breast cancer amongst screen detected cases in 2008/9 was 8.3%. The phenotype of HER2+ breast cancer was stable following the introduction of universal testing. The overall rate of HER2+ breast cancer was influenced by screen detection.</description><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2012.09.001</identifier><identifier>PMID: 23099207</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Age Distribution ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Early Detection of Cancer - methods ; Early Detection of Cancer - standards ; Female ; Hematology, Oncology and Palliative Medicine ; HER2 ; Humans ; Logistic Models ; Lymphatic Metastasis ; Mammography ; Middle Aged ; Neoplasm Grading ; New South Wales ; Pathology ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Tumor Burden</subject><ispartof>Breast (Edinburgh), 2012-12, Vol.21 (6), p.724-729</ispartof><rights>2012</rights><rights>Copyright © 2012. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-6a6d5687e4932e0b4cd599179a0c8169e25ed79d8229f93f7a4d1d8364b4318e3</citedby><cites>FETCH-LOGICAL-c496t-6a6d5687e4932e0b4cd599179a0c8169e25ed79d8229f93f7a4d1d8364b4318e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.breast.2012.09.001$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23099207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pathmanathan, Nirmala</creatorcontrib><creatorcontrib>Provan, Pamela J</creatorcontrib><creatorcontrib>Mahajan, Hema</creatorcontrib><creatorcontrib>Hall, Geoffrey</creatorcontrib><creatorcontrib>Byth, Karen</creatorcontrib><creatorcontrib>Bilous, A. Michael</creatorcontrib><creatorcontrib>Balleine, Rosemary L</creatorcontrib><title>Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>Abstract The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of universal testing. In 2003/4, 43.3% of breast cancers were tested for HER2 with 16% of tested cases HER2+. In 2008/9, 98.4% of cases were tested with 14.7% HER2+. In 2008/9, HER2+ status was associated with younger age, higher grade, increased tumour size, lymph node involvement, negative oestrogen and/or progesterone receptor status. HER2+ cases diagnosed in 2003/4 were not significantly different in respect of these features. The rate of HER2+ breast cancer amongst screen detected cases in 2008/9 was 8.3%. The phenotype of HER2+ breast cancer was stable following the introduction of universal testing. The overall rate of HER2+ breast cancer was influenced by screen detection.</description><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Early Detection of Cancer - methods</subject><subject>Early Detection of Cancer - standards</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HER2</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Lymphatic Metastasis</subject><subject>Mammography</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>New South Wales</subject><subject>Pathology</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Tumor Burden</subject><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2PFCEURYnROO3oPzCmlm6qfEA1FBsT0xkdk0lM_FgTGl710FZDC9SY-fdS1ujCjSs299wbziPkJYWOAhVvjt0-ocmlY0BZB6oDoI_Ihm45azkM8JhsQAlolZTigjzL-QgAiovhKblgHJRiIDfktLs1ydiCyefibW7i2FxffWbtOWZf_B0260pjTbCYGufNIcSMrhnjNMWfPhyacouNDyVFN9viY1g65lDZlM30u60pWNvD4Tl5Mpop44uH95J8e3_1dXfd3nz68HH37qa1vRKlFUa4rRgk9oozhH1v3VYpKpUBO1ChkG3RSeUGxtSo-ChN76gbuOj3PacD8kvyeu09p_hjrtv65LPFaTIB45w1pXIQkqqe1mi_Rm2KOScc9Tn5k0n3moJeROujXhXoRbQGpavoir16WJj3J3R_oT9ma-DtGsD6zzuPSWfrsTp0PqEt2kX_v4V_C-zkg7dm-o73mI9xTqE61FTnyugvy7GXW1NW6UFK_gsHZKYw</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Pathmanathan, Nirmala</creator><creator>Provan, Pamela J</creator><creator>Mahajan, Hema</creator><creator>Hall, Geoffrey</creator><creator>Byth, Karen</creator><creator>Bilous, A. Michael</creator><creator>Balleine, Rosemary L</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121201</creationdate><title>Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing</title><author>Pathmanathan, Nirmala ; Provan, Pamela J ; Mahajan, Hema ; Hall, Geoffrey ; Byth, Karen ; Bilous, A. Michael ; Balleine, Rosemary L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-6a6d5687e4932e0b4cd599179a0c8169e25ed79d8229f93f7a4d1d8364b4318e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Early Detection of Cancer - methods</topic><topic>Early Detection of Cancer - standards</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HER2</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Lymphatic Metastasis</topic><topic>Mammography</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>New South Wales</topic><topic>Pathology</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pathmanathan, Nirmala</creatorcontrib><creatorcontrib>Provan, Pamela J</creatorcontrib><creatorcontrib>Mahajan, Hema</creatorcontrib><creatorcontrib>Hall, Geoffrey</creatorcontrib><creatorcontrib>Byth, Karen</creatorcontrib><creatorcontrib>Bilous, A. Michael</creatorcontrib><creatorcontrib>Balleine, Rosemary L</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pathmanathan, Nirmala</au><au>Provan, Pamela J</au><au>Mahajan, Hema</au><au>Hall, Geoffrey</au><au>Byth, Karen</au><au>Bilous, A. Michael</au><au>Balleine, Rosemary L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>21</volume><issue>6</issue><spage>724</spage><epage>729</epage><pages>724-729</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><abstract>Abstract The aim of this study was to determine the impact of universal HER2 testing on the clinico-pathologic profile of HER2+ breast cancer. Data were extracted from breast cancer pathology reports spanning two periods: before (2003/4, n = 379), and after (2008/9, n = 560) the introduction of universal testing. In 2003/4, 43.3% of breast cancers were tested for HER2 with 16% of tested cases HER2+. In 2008/9, 98.4% of cases were tested with 14.7% HER2+. In 2008/9, HER2+ status was associated with younger age, higher grade, increased tumour size, lymph node involvement, negative oestrogen and/or progesterone receptor status. HER2+ cases diagnosed in 2003/4 were not significantly different in respect of these features. The rate of HER2+ breast cancer amongst screen detected cases in 2008/9 was 8.3%. The phenotype of HER2+ breast cancer was stable following the introduction of universal testing. The overall rate of HER2+ breast cancer was influenced by screen detection.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>23099207</pmid><doi>10.1016/j.breast.2012.09.001</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-9776 |
| ispartof | Breast (Edinburgh), 2012-12, Vol.21 (6), p.724-729 |
| issn | 0960-9776 1532-3080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1178671941 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Age Distribution Aged Aged, 80 and over Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Neoplasms - pathology Early Detection of Cancer - methods Early Detection of Cancer - standards Female Hematology, Oncology and Palliative Medicine HER2 Humans Logistic Models Lymphatic Metastasis Mammography Middle Aged Neoplasm Grading New South Wales Pathology Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tumor Burden |
| title | Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%20HER2-positive%20breast%20cancer%20diagnosed%20following%20the%20introduction%20of%20universal%20HER2%20testing&rft.jtitle=Breast%20(Edinburgh)&rft.au=Pathmanathan,%20Nirmala&rft.date=2012-12-01&rft.volume=21&rft.issue=6&rft.spage=724&rft.epage=729&rft.pages=724-729&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2012.09.001&rft_dat=%3Cproquest_cross%3E1178671941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1178671941&rft_id=info:pmid/23099207&rft_els_id=1_s2_0_S0960977612001877&rfr_iscdi=true |